OptimizeRx Corporation (OPRX) reported fourth-quarter 2025 revenue of $32.24 million, down 0.24% year over year and slightly above the consensus estimate of $31.72 million.
Gross profit improved to $24.10 million (+9.43% YoY) while cost of sales fell to $8.14 million (-20.93% YoY). Operating profit rose to $8.57 million (+135.8% YoY). Net income attributable to common shareholders was $5.02 million (reported change -6535.9% YoY) and diluted earnings per share were $0.26.
Operating cash flow increased to $7.34 million (+3606.06% YoY). Purchases of property, plant and equipment were -$11,000 (down 35.29% YoY). Cash and cash equivalents rose to $23.37 million (+74.63% YoY) and total liabilities decreased to $48.62 million (-10.24% YoY).
Reported diluted EPS of $0.26 topped the estimate of $0.23. The stock moved significantly after the release, changing by 14.5% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
OptimizeRx Corporation Insider Trading Activity
OptimizeRx Corporation insiders have traded $OPRX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $OPRX stock by insiders over the last 6 months:
- STEPHEN L SILVESTRO (Chief Executive Officer) sold 1,620 shares for an estimated $30,375
- EDWARD STELMAKH (Chief Finance & Strat Officer) sold 1,388 shares for an estimated $18,751
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
OptimizeRx Corporation Hedge Fund Activity
We have seen 62 institutional investors add shares of OptimizeRx Corporation stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NEXT CENTURY GROWTH INVESTORS LLC added 294,688 shares (+139.8%) to their portfolio in Q4 2025, for an estimated $3,612,874
- CENTERBOOK PARTNERS LP removed 283,585 shares (-91.8%) from their portfolio in Q4 2025, for an estimated $3,476,752
- D. E. SHAW & CO., INC. removed 208,184 shares (-64.8%) from their portfolio in Q4 2025, for an estimated $2,552,335
- INVESCO LTD. removed 199,091 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,440,855
- HARVEST INVESTMENT SERVICES, LLC removed 167,837 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,057,681
- BALYASNY ASSET MANAGEMENT L.P. removed 156,338 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,204,929
- G2 INVESTMENT PARTNERS MANAGEMENT LLC added 130,264 shares (+72.5%) to their portfolio in Q4 2025, for an estimated $1,597,036
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
OptimizeRx Corporation Analyst Ratings
Wall Street analysts have issued reports on $OPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/07/2025
- JMP Securities issued a "Market Outperform" rating on 10/10/2025
To track analyst ratings and price targets for OptimizeRx Corporation, check out Quiver Quantitative's $OPRX forecast page.
OptimizeRx Corporation Price Targets
Multiple analysts have issued price targets for $OPRX recently. We have seen 3 analysts offer price targets for $OPRX in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Jeff Garro from Stephens & Co. set a target price of $17.0 on 11/17/2025
- Constantine Davides from Citizens set a target price of $24.0 on 11/07/2025
- Constantine Davides from JMP Securities set a target price of $23.0 on 10/10/2025
